Professor & Senior VP- Neuroscience Drug DiscoverySanford Burnham Prebys Medical Discovery Institute
Neuroscience, Alzheimer's Disease, Multiple Sclerosis (MS), Parkinson's Disease
Associate Professor of Neurosurgery, Radiation oncUniversity of California, Los Angeles (UCLA), Health Sciences
Neurosurgery, Neuroscience, Brain Tumor, Hearing, Balance, Radiosurgery, UCLA, David Geffen School of Medicine at UCLA
Isaac Yang, M.D., is a nationally renowned neurosurgeon specializing in brain tumors, superior semicircular canal dehiscence (SSCD), and skull base brain surgery at UCLA. Yang is a board-certified neurosurgeon and director of medical student education for the UCLA Department of Neurosurgery; an associate professor of neurosurgery, head and neck surgery, and radiation oncology at the David Geffen School of Medicine at UCLA, and a principal investigator at the UCLA brain tumor laboratory. Yang is highly sought out by peers, patients and the media for his expertise in neurological diseases and brain health. He has made multiple TV appearances on Good Morning America, CBS' The Doctors, Dr. Drew LifeChangers, and several national news outlets. Originally from Lodi, Calif., Yang developed an interest in neurobiology as an undergraduate. He earned his bachelor’s degree with Phi Beta Kappa from the University of California, Berkeley. His training followed with a medical degree from the David Geffen School of Medicine at UCLA. Yang completed a neurological surgery residency at the University of California San Francisco, as well as an NRSA NIH-funded F32 postdoctoral brain tumor research fellowship. Yang’s clinical focus has been primarily on brain tumors, both glioblastoma and skull base tumors. His research efforts have examined antigen expression and manipulation of the immune response to glioblastoma. His work was recognized by a UCSF Clinical and Translational Scientist Training Award and the CNS Dandy Clinical Research Fellowship. Yang has been the recipient of several distinguished regional and national awards, including the UCSF Medical Center 2010 Exceptional Physician Award, the AANS Integra Brain Tumor Research Award, San Francisco Neurological Society Edwin Boldrey Award for Basic Science Research, American Academy of Neurological and Orthopedic Surgeons Research Award, Kaiser Award for Clinical Research, the national AANS Leksell Radiosurgery Award, and the Tumor Section Ronald L. Bittner Award on Brain Tumor Research. Yang has published more than 150 publications in peer-reviewed journals and authored more than half a dozen book chapters. At UCLA, he is investigating the use of nanoparticles and nanotechnology for their application in brain tumor immunotherapy and vaccines. Dr. Isaac Yang is dedicated to improving the care and treatment of all patients undergoing neurosurgery. If interested please follow Dr. Yang on Facebook at Isaac Yang UCLA Neurosurgery or find his most recent book, Service Minded Physician, on Amazon.
Director, UCLA Steve Tisch BrainSPORT ProgramUniversity of California, Los Angeles (UCLA), Health Sciences
Concussion, concussion and football, traumatic brain injuries, Youth, Neuroplasticity, post-traumatic epilepsy, concussion and sports, Sports-Related Head Injury, Brain Development, helmet studies, Neuroimaging, Genetic Markers
Before joining UCLA, Giza worked on the Yosemite Search and Rescue team. In 2011, he traveled to Afghanistan as a civilian advisor to the U.S. Department of Defense. He co-chaired the American Academy of Neurology committee that developed an evidence-based practice guideline for the management of sports concussions from 2009-2013. He currently serves on advisory committees for traumatic brain injuries/concussion with the U.S. Centers for Disease Control, National Collegiate Athletic Association, Major League Soccer and U.S. Soccer Federation. He has been a clinical consultant for the National Football League, National Hockey League and Major League Soccer.
Assistant Professor of Health and Wellness StudiesBinghamton University, State University of New York
Nutrigenomics, Neurodegeneration, Nutrition, Mental Distress, Microbiota, Food
Dr. Crotty received his B.S. in Biology from the Massachusetts Institute of Technology (MIT) in 1996. He also received a B.S. in Writing from MIT the same year. Dr. Crotty undertook graduate work in virology at the University of California, San Francisco in the Program in Biological Sciences. There he discovered the mechanism of action of the antiviral drug ribavirin, widely used to treat chronic hepatitis C infections. Dr. Crotty earned his Ph.D. in Biochemistry and Molecular Biology in 2001. He then pursued postdoctoral work at the Emory University Vaccine Center with Dr. Rafi Ahmed from 2001 to 2003, studying aspects of the generation and maintenance of immune memory after viral infections. In 2003, he accepted a faculty position at LJI. The Crotty lab has helped established that follicular helper T cells (Tfh) are a distinct type of differentiated CD4 T cell uniquely specialized in B cell help, and that Tfh differentiation is controlled by the transcription factor Bcl6 (Science 2009). He has made major advances in the area of T cell help to B cells, and through this work has become an internationally recognized leader in the field of Tfh cell biology (Annual Review of Immunology 2011). Dr. Crotty was named a Pew Scholar in Biomedical Sciences in 2005, and was the recipient of the annualAmerican Association of Immunologists (AAI) Investigator Award for outstanding early-career research contributions to the field of Immunology in 2012. Dr. Crotty is also the author of Ahead of the Curve, a biography of Nobel laureate scientist David Baltimore, published in 2001, and reviewed in The Wall Street Journal, Nature, The Washington Post, The Journal of the American Medical Association (JAMA), Nature Medicine, and Discover Magazine.
Dr Katy Hayward is one of the leading political sociologists on the island of Ireland, and is a Reader in Sociology, and Senior Research Fellow at the Senator George J. Mitchell Institute for Global Peace, Security and Justice at Queen’s University Belfast. Dr Hayward’s research focuses on conflict/post-conflict transitions and is actively interdisciplinary, traversing fields of border studies, conflict studies, European studies, and Irish studies. This means that she is particularly well-placed to speak about the implications of Brexit for the island of Ireland, and Northern Ireland in particular, European integration, political violence, and the application of discourse analysis.
Professor, Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO. Research has focused on neural mechanisms of adaptation to alcohol, including tolerance and dependence. Identified a role of peptide hormones and brain growth factors to modify alcohol tolerance. Discovered that one subtype of glutamate receptor, the NMDA receptor, is very sensitive to alcohol, and that increases in NMDA receptor function are involved in alcohol dependence. This work has led to many further studies by others that focus on the role of the brain glutamate systems in addiction to alcohol and other drugs. Currently focus on systems genetic analysis, using "big data" to understand the genetic contribution to alcohol-related and other complex behaviors.
I have almost 40 years of experience in the field of alcoholism research, with much of my work focusing on the molecular sites and mechanisms of alcohol action in brain. My group has extensive experience with mouse behavioral models of alcohol consumption and dependence and was involved in some of the initial studies of the neuroimmune basis of alcohol dependence. Profiling brain gene expression is key to understanding addiction, and we were among the first to study the human brain transcriptome. We have implemented microRNA profiling and next-generation sequencing to extend our studies of molecular remodeling by alcohol in human and mouse brain. We study the genetic overlap in human alcoholics and animal models of alcohol dependence and examine the neurobiological systems involved. My research encompasses the fields of genomics, behavior, systems biology, and bioinformatics. Overall, my work has combined functional, structural, behavioral, and genomic approaches to define sites of alcohol action. Currently, I am Associate Director of the Waggoner Center for Alcohol and Addiction Research at The University of Texas at Austin and previously served as Director for 20 years. I am also the Consortium Director for the Integrative Neuroscience Initiative on Alcoholism (INIA)-Neuroimmune, where our goal is to identify and test candidate drugs that may be repurposed to treat alcohol use disorders.
Doctor and cognitive neuroscientistThe Neuro - Montreal Neurological Institute and Hospital
Decision Making, AIDS, Cognition, Neuroscience, Cognition Dysfunction
Dr. Lesley Fellows is a neurologist specializing in disorders of cognition. She has a particular interest in the functions of the brain's frontal lobes. Her research program focuses on the brain basis of decision making in humans, using the tools of cognitive neuroscience. She studies how focal brain damage or neurochemical dysfunction affects all aspects of decision making, how options are generated and organized, how they are valued and compared, and how choices are made. She is also interested in more general questions about the roles of the frontal lobes in the regulation of emotion, the expression of personality traits, and the representation of past and future information. This work has relevance for understanding impaired executive function following frontal lobe injury from aneurysm rupture, stroke, or tumor growth, as well as in degenerative conditions such as Parkinson’s Disease and some forms of dementia. It also provides insights into how the component processes that underlie decision making are carried out in the intact brain.
Memory & Cognitive Processes, Memory, Neuroscience, Memory and Cognition, memory bias, memory accuracy
Wayne Sossin is interested in the biochemical changes that occur in the brain during learning and memory. Of particular interest is the identification of molecular memory traces that underlie behavioural memory. Sossin's laboratory examines this problem in the simple nervous system of Aplysia, where behavioural memory is encoded by changes in the synaptic strength of identified neurons. In this system, one can visualize memory using modern imaging techniques and electrophysiology, and thus investigate the underlying molecular basis of memory. His laboratory is investigating several candidates for the molecular trace, including the activation of persistent kinases and the regulated translation of new proteins.
Erica Ollmann Saphire, Ph.D. is a Professor of the La Jolla Institute for Immunology and one of the world’s leading experts in pandemic and emerging viruses, such as Ebola, Marburg and Lassa. Dr. Saphire directs the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), an NIH-funded Center of Excellence in Translational Research. The VIC unites 43 previously competing academic, industrial and government labs across five continents to understand which antibodies are most effective in patients and to streamline the research pipeline to provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Dr. Saphire's research explains, at the molecular level, how and why viruses like Ebola and Lassa are pathogenic and provides the roadmap for developing antibody-based treatments. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses. A recent discovery revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa. Dr. Saphire is the recipient of numerous accolades and grants, including the Presidential Early Career Award in Science and Engineering presented by President Obama at the White House; the Gallo Award for Scientific Excellence and Leadership from the Global Virus Network; young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, American Society for Biochemistry and Molecular Biology, and the MRC Centre for Virus Research in the United Kingdom; the Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, and the Surhain Sidhu award for the most outstanding contribution to the field of diffraction by a person within five years of the Ph.D. Dr. Saphire has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from the German research foundation, Deutsche Forschungsgemeinschaft, to develop international collaborations around human health and molecular imaging through cryoelectron microscopy. Dr. Saphire received a B.A. in biochemistry and cell biology and ecology and evolutionary biology from Rice University in Houston, Texas, and a Ph.D. in molecular biology from Scripps Research. She stayed on at Scripps Research as a Research Associate to conduct postdoctoral research and rose through the ranks to become a Professor in the Department of Immunology and Microbiology. In early 2019, Dr. Saphire joined La Jolla Institute for Immunology to establish a molecular imaging facility for cryo-electron microscopy (cryo-EM) at the Institute. The extremely detailed images produced by cryo-EM reveal precisely how essential mechanisms of the immune system operate.
Professor of Biomedical AnthropologyBinghamton University, State University of New York
Disease, Neurodegenerative Disorder, Amyothrophic Lateral Sclerosis, Parkinson's Disease, Alzheimer's Disease, Food Chain, Obesity, Malaria
Garruto’s research interests include natural experimental models of disease, using both field and laboratory approaches. His cross-disciplinary research and interests include studies of neurodegenerative disorders including amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease, food chain disorders, health transition studies, obesity and bionutrition, malaria, Lyme and other tick-borne diseases, and prion diseases, especially chronic wasting disease.
Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise. With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health. Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium. As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally. Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.
Medical Director, Cellular Immunotherapy Integrated Research Center at Fred HutchFred Hutchinson Cancer Research Center
CAR T-cell therapy, Immunotherapy, Chimeric antigen receptor T-cell, Lymphoma, Leukemia, Myeloma, cancer immunotherapies, Blood Cancers, ofatumumab, Arzerra, Hematopoietic
Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T’s and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation. He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market – one that has transformed the treatment of certain leukemias and lymphomas. He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT. Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous “graft-vs-host” effects on normal tissues. Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra®) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant “conditioning” or as “maintenance” to extend remissions after allogeneic transplantation. As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch’s clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.